Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | dual specificity protein phosphatase | 0.0162 | 0.1519 | 0.5 |
Echinococcus granulosus | EGFP:Bcl2 fusion protein | 0.0684 | 0.9137 | 1 |
Leishmania major | pteridine reductase 1 | 0.0058 | 0 | 0.5 |
Brugia malayi | Dual specificity phosphatase, catalytic domain containing protein | 0.0162 | 0.1519 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0743 | 1 | 1 |
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | 0.0684 | 0.9137 | 1 |
Onchocerca volvulus | 0.0162 | 0.1519 | 1 | |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0743 | 1 | 0.5 |
Giardia lamblia | Dual specificity phosphatase, catalytic | 0.0162 | 0.1519 | 0.5 |
Loa Loa (eye worm) | dual specificity phosphatase | 0.0162 | 0.1519 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.0743 | 1 | 0.5 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0058 | 0 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0743 | 1 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0743 | 1 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0743 | 1 | 0.5 |
Leishmania major | oxidoreductase-like protein | 0.0058 | 0 | 0.5 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0058 | 0 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0743 | 1 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0743 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.